IN THIS ARTICLE
What should I discuss with my health care provider before receiving alemtuzumab (Campath)?
You should not receive alemtuzumab if you are allergic to it.
To make sure alemtuzumab is safe for you, tell your doctor if you have any of these other conditions:
FDA pregnancy category C. It is not known whether alemtuzumab will harm an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant while receiving this medication.
It is not known whether alemtuzumab passes into breast milk or if it could harm a nursing baby. You should not breast-feed while you are receiving alemtuzumab.
How is alemtuzumab given (Campath)?
Alemtuzumab is injected into a vein through an IV. You will receive this injection in a clinic or hospital setting. Alemtuzumab must be given slowly, and the IV infusion can take up to up to 2 hours to complete.
This medication is usually given for a total or 12 weeks. You may receive the medication every day or 3 days per week, depending on any side effects that occur.
If you have stopped receiving alemtuzumab for longer than 7 days for any reason, you may need to restart the medication at a lower dose.
You may be given an antibiotic and other medications to help prevent certain side effects of alemtuzumab. Take these medicines for the full prescribed length of time, which may include at least 2 months after you stop receiving alemtuzumab.
Alemtuzumab can lower blood cells that help your body fight infections and help your blood to clot. Your blood will need to be tested often. Your cancer treatments may be delayed based on the results of these tests. Visit your doctor regularly.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Need help identifying pills and medications?
- CML Treatment: How to Stick To Your Plan
- Treatments for Multiple Myeloma
- Talking to Your Doctor About CLL